Hanmi Pharm's Future Growth Engine 'Digital Healthcare'... President Lim Juhyun Leads TF Fully

Business Promotion TF Launch Ceremony... Including Key Executives
Synergy Among Affiliates in Prevention Management and Diagnostic Treatment

Hanmi Pharmaceutical Group has launched a task force (TF) to establish digital healthcare as a new growth engine and has begun full-scale business promotion.

Choi In-young, Head of R&D Center; Kim Na-young, Head of New Product Development Division; Lim Joo-hyun, President; Park Jae-hyun, CEO; Park Myung-hee, Head of Domestic Business Division; and Kyung Dae-sung, Executive Director of Strategic Marketing Team (from left in the front row), along with other key executives of Hanmi Pharmaceutical Group, are posing for a commemorative photo at the launch ceremony of the Digital Healthcare Business Promotion TF.
[Photo by Hanmi Pharmaceutical]

On the 20th, Hanmi Pharmaceutical Group announced that it recently held a launch ceremony for the digital healthcare business promotion TF at its headquarters in Songpa-gu, Seoul, and plans to promote a multi-layered digital healthcare business that can converge in areas such as prevention and management, diagnosis, and treatment.

The TF includes key executives from the group, centered on Lim Ju-hyun, President of Hanmi Pharmaceutical Group (Head of Strategic Planning at Hanmi Science), including Park Jae-hyun, CEO of Hanmi Pharmaceutical, Choi In-young, Head of R&D Center (Executive Director), Kim Na-young, Head of New Product Development Division (Executive Director), Park Myung-hee, Head of Domestic Business Division (Executive Director), and Kyung Dae-sung, Executive Director of Strategic Marketing Team. Through this, they aim to strengthen Hanmi Pharmaceutical’s unique digital healthcare competitiveness under the slogan “Digital Healthcare as a Growth Engine for the Next 50 Years.”

In particular, based on the unparalleled experience accumulated in business development, marketing and sales, and regulatory approval in the pharmaceutical and bio sectors, they aspire to lead the rapidly growing digital healthcare market in the areas of ▲ prevention and management ▲ diagnosis and treatment. Hanmi Pharmaceutical has leveraged its strength in optimizing sales and supply chains using digital technology since the 2000s, entering into a joint investment with KT in Digital Pharm, a company specializing in digital therapeutics (DTx), and is also promoting research and development (R&D) collaboration using artificial intelligence (AI) for anticancer drug development with Eisen Science.

Each affiliate also plans to create synergy with their core businesses. Hanmi Science will focus on health functional foods, Hanmi Pharmaceutical on sales, marketing, R&D, and data science, Online Pharm on kiosks, Digital Pharm on DTx and clinical decision support systems (CDSS), JVM on automatic dispensing machines, and Evidnet on MyData, leveraging their expertise in these fields.

Kyung Dae-sung, Executive Director in charge of overall TF operations, said, “We will consolidate the capabilities and expertise of each Hanmi Pharmaceutical group company to firmly establish our position as a leading company in the digital healthcare market.”